
US FDA approves BlackfinBio’s gene therapy trial for hereditary spastic paraplegia
The US Food and Drug Administration has cleared BlackfinBio’s investigational new drug (IND) application for a Phase I/II trial of BFB-101, an adeno-associated virus gene therapy designed to treat hereditary spastic paraplegia type 47 (SPG47). The open …